AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19167725 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting to urinate with a password
Number of subjects: 570
Study 19167725 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward system
Number of subjects: 570
Study 17472761 — intervention group
Group type: EXPERIMENTAL
Intervention: PSST approach (TAU+PSST+FT)
Number of subjects: 82
Study 17472761 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 82
Study 14751210 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepsy surgery
Number of subjects: 20
Study 14751210 — intervention group
Group type: COMPARATOR
Intervention: No surgery (control group)
Number of subjects: 20
Study 11346805 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography guided treatment
Number of subjects: 1222
Study 11346805 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 1222
Study 9288409 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital sodium (2.9 mg/kg body weight)
Number of subjects: 12
Study 9288409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8506770 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis (ceftriazone, 1 gr intramuscular)
Number of subjects: 2284
Study 8506770 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 2284
Study 3015654 — intervention group
Group type: EXPERIMENTAL
Intervention: TS stretch reflex
Number of subjects: 0
Study 3015654 — intervention group
Group type: EXPERIMENTAL
Intervention: TA stretch reflex
Number of subjects: 0
Study 30670840 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shockwave therapy (Li-ESWT)
Number of subjects: 0
Study 30670840 — intervention group
Group type: COMPARATOR
Intervention: Sham control (not yet implemented)
Number of subjects: 0
Study 28160719 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 250
Study 25957367 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging-appropriateness guidelines and estimated radiation exposure information
Number of subjects: 0
Study 25957367 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated radiation information then guidelines
Number of subjects: 0
Study 23143503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 42
Study 23143503 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate/dexamethasone
Number of subjects: 42
Study 21765198 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise protocol for the treatment of pain (paracetamol, morphine, buprenorphine transdermal patch, pregabaline) for eight weeks
Number of subjects: 352
Study 21765198 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise protocol for the treatment of pain
Number of subjects: 352
Study 21765198 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (control)
Number of subjects: 352
Study 19064811 — intervention group
Group type: EXPERIMENTAL
Intervention: ARRIVE trial
Number of subjects: 0
Study 19064811 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prevention trial in development
Number of subjects: 0
Study 16859142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ventilation once every 5 minutes during CPB
Number of subjects: 36
Study 16859142 — intervention group
Group type: COMPARATOR
Intervention: No ventilation during CPB
Number of subjects: 36
Study 12750665 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-phase treatment with bionator
Number of subjects: 208
Study 12750665 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-phase treatment with headgear/biteplate
Number of subjects: 208
Study 12750665 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-phase treatment
Number of subjects: 208
Study 12750665 — intervention group
Group type: COMPARATOR
Intervention: 1-phase treatment
Number of subjects: 208
Study 11148916 — intervention group
Group type: EXPERIMENTAL
Intervention: Epileptic patients
Number of subjects: 32
Study 11148916 — intervention group
Group type: COMPARATOR
Intervention: Control group (29 healthy age-matched subjects)
Number of subjects: 32
Study 8795760 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical verapamil 0.063%, 0.125%, and 0.25%
Number of subjects: 12
Study 8795760 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical verapamil 0.25%
Number of subjects: 12
Study 8795760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1618257 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 0
Study 6152055 — intervention group
Group type: EXPERIMENTAL
Intervention: IV alprazolam (1.0 mg)
Number of subjects: 6
Study 6152055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alprazolam (1.0 mg)
Number of subjects: 6
Study 6152055 — intervention group
Group type: COMPARATOR
Intervention: IV and oral alprazolam (1.0 mg)
Number of subjects: 6
Study 31553712 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection (experimental neck pain)
Number of subjects: 28
Study 31553712 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 28
Study 28456615 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabajadora de Salud
Number of subjects: 14
Study 28456615 — intervention group
Group type: COMPARATOR
Intervention: Telephone only control group
Number of subjects: 14
Study 26724641 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg/d) plus gefitinib (250 mg/d)
Number of subjects: 71
Study 26724641 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (1 mg/d) plus placebo
Number of subjects: 71
Study 25358909 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity self-management intervention (4 self-management sessions)
Number of subjects: 228
Study 25358909 — intervention group
Group type: COMPARATOR
Intervention: Generic health information (control)
Number of subjects: 228
Study 22056350 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible RFM
Number of subjects: 49
Study 22056350 — intervention group
Group type: COMPARATOR
Intervention: Masked RFM
Number of subjects: 49
Study 21442588 — intervention group
Group type: EXPERIMENTAL
Intervention: Eagle Tactical Athlete Program (ETAP)
Number of subjects: 0
Study 21442588 — intervention group
Group type: COMPARATOR
Intervention: Current physical training at Fort Campbell
Number of subjects: 0
Study 18612534 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (specific dosage and duration not mentioned)
Number of subjects: 19274
Study 18612534 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on six variables (age >75 years, recent bleeding, cancer, creatinine levels >1.2 mg/dl, anemia, pulmonary embolism)
Number of subjects: 19274
Study 15701464 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training (5 days/week, submaximal bicycle ergometer training, 30 min/day; calisthenics 9 min/day) for 8 weeks
Number of subjects: 18
Study 15701464 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training
Number of subjects: 18
Study 15701464 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study 11835202 — intervention group
Group type: COMPARATOR
Intervention: CFC flunisolide 1000 microg without spacer
Number of subjects: 12
Study 11835202 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA flunisolide 340 microg with spacer
Number of subjects: 12
Study 11835202 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA flunisolide 516 microg without spacer
Number of subjects: 12
Study 11835202 — intervention group
Group type: COMPARATOR
Intervention: CFC flunisolide
Number of subjects: 12
Study 10392324 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled triamcinolone acetonide (800 mcg)
Number of subjects: 0
Study 10392324 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous triamcinolone acetonide (400 mcg)
Number of subjects: 0
Study 10392324 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled triamcinolone acetonide (800 mcg) with oral charcoal
Number of subjects: 0
Study 10392324 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 0
Study 8721464 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled premedication by i.v. midazolam (mean dose 0.7 mg, 0.7-1.1 mg for anxious patients, 1.7 mg for those using the device)
Number of subjects: 50
Study 8721464 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of 4 mg i.v. midazolam (1-hour infusion)
Number of subjects: 50
Study 1949366 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant CAP plus radiation
Number of subjects: 40
Study 1949366 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 6338996 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical mattress monofilament nylon sutures
Number of subjects: 341
Study 6338996 — intervention group
Group type: COMPARATOR
Intervention: Steel clips which penetrated only the dermis
Number of subjects: 341
Study 31752850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg
Number of subjects: 667
Study 31752850 — intervention group
Group type: COMPARATOR
Intervention: Pitavastatin 4 mg
Number of subjects: 667
Study 30058609 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedures for estimating biological occupational exposure limits (BOELs) using regression analysis on 14 organic solvents.
Number of subjects: 14
Study 26728964 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversational search engine interface (n=43)
Number of subjects: 89
Study 24217949 — intervention group
Group type: EXPERIMENTAL
Intervention: Yukon-DES (polymer-free sirolimus-eluting stent)
Number of subjects: 701
Study 22511033 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based behavioral pain management intervention
Number of subjects: 26
Study 19393473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate, 1 mg/kg, perioperatively and then at 1, 4, 8, and 12 months
Number of subjects: 93
Study 19393473 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 93
Study 19393473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 93
Study 17967593 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 173
Study 17967593 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 173
Study 15341354 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (160 mJ/pulse, 10 Hz)
Number of subjects: 20
Study 15341354 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic instrument (UI)
Number of subjects: 20
Study 11070961 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 57
Study 11070961 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 57
Study 11070961 — intervention group
Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 57
Study 9060896 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy endocavitary cardioversion during exercise
Number of subjects: 16
Study 9060896 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy endocavitary cardioversion at rest
Number of subjects: 16
Study 9060896 — intervention group
Group type: EXPERIMENTAL
Intervention: First shock sequence
Number of subjects: 16
Study 9060896 — intervention group
Group type: EXPERIMENTAL
Intervention: Second shock sequence
Number of subjects: 16
Study 9060896 — intervention group
Group type: EXPERIMENTAL
Intervention: Discomfort score at rest
Number of subjects: 16
Study 9060896 — intervention group
Group type: EXPERIMENTAL
Intervention: Discomfort score during exercise
Number of subjects: 16
Study 8397999 — intervention group
Group type: EXPERIMENTAL
Intervention: One pill each day for < or = 63 weeks
Number of subjects: 19
Study 8397999 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring
Number of subjects: 19
Study 8397999 — intervention group
Group type: EXPERIMENTAL
Intervention: Early changes in compliance
Number of subjects: 19
Study 3522347 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride treatment
Number of subjects: 44
Study 3522347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 2853038 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 100 mg
Number of subjects: 6
Study 2853038 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 1 mg
Number of subjects: 6
Study 2853038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31392960 — intervention group
Group type: EXPERIMENTAL
Intervention: sNEP levels in HFpEF patients
Number of subjects: 242
Study 31392960 — intervention group
Group type: EXPERIMENTAL
Intervention: sNEP levels in HFpEF patients after adjustment
Number of subjects: 242
Study 31392960 — intervention group
Group type: EXPERIMENTAL
Intervention: sNEP levels in propensity matched cohorts
Number of subjects: 242
Study 29984564 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic physical training (APT) performed twice a week for 16 weeks
Number of subjects: 54
Study 29984564 — intervention group
Group type: COMPARATOR
Intervention: 16 weeks of detraining after APT
Number of subjects: 54
Study 28807403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricemia in HFrEF patients
Number of subjects: 324
Study 28807403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricemia in HFpEF patients
Number of subjects: 324
Study 28807403 — intervention group
Group type: EXPERIMENTAL
Intervention: Congestion score ≥3 in HFrEF patients
Number of subjects: 324
Study 26255288 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer training (SOC, n = 21)
Number of subjects: 83
Study 26255288 — intervention group
Group type: COMPARATOR
Intervention: Control group (C, n = 20)
Number of subjects: 83
Study 26255288 — intervention group
Group type: COMPARATOR
Intervention: Moderate‐intensity swimming (MS, n = 21)
Number of subjects: 83
Study 26255288 — intervention group
Group type: COMPARATOR
Intervention: High‐intensity intermittent swimming (HS, n = 21)
Number of subjects: 83
Study 23212605 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Cancer Survivor Study Needs Assessment Questionnaire (CCSS‐NAQ)
Number of subjects: 1178
Study 21562755 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg once daily
Number of subjects: 32
Study 21562755 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg once daily
Number of subjects: 32
Study 21562755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19017423 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol ester spreads
Number of subjects: 21
Study 17052967 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF during radiotherapy (group B)
Number of subjects: 10
Study 17052967 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (group A)
Number of subjects: 10
Study 14749930 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exposure to noise and whole-body vibration (high intensity: 86 dB(A)/2.5 m/s2)
Number of subjects: 54
Study 14749930 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity group (86 dB(A)/2.5 m/s2)
Number of subjects: 54
Study 14749930 — intervention group
Group type: COMPARATOR
Intervention: Low intensity (77 dB(A) noise and 1.0 m/s2 vibration) and medium intensity (81 dB(A)/1.6 m/s2)
Number of subjects: 54
Study 10654491 — intervention group
Group type: EXPERIMENTAL
Intervention: Drew‐Anderson Technique (bilateral extracorporeal circulation using patient's lung as oxygenator)
Number of subjects: 30
Study 10654491 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiopulmonary bypass procedure (control group)
Number of subjects: 30
Study 10654491 — intervention group
Group type: EXPERIMENTAL
Intervention: Drew‐Anderson Technique
Number of subjects: 30
Study 9257360 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygroscopic condenser humidifier (HCH) during quiet breathing
Number of subjects: 21
Study 9257360 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygroscopic condenser humidifier (HCH) during maximal voluntary ventilation (MVV)
Number of subjects: 21
Study 9257360 — intervention group
Group type: COMPARATOR
Intervention: Without HCH during quiet breathing
Number of subjects: 21
Study 9257360 — intervention group
Group type: COMPARATOR
Intervention: Without HCH during maximal voluntary ventilation (MVV)
Number of subjects: 21
Study 8227822 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (n = 114)
Number of subjects: 224
Study 8227822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 110)
Number of subjects: 224
Study 3081399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 86
Study 3081399 — intervention group
Group type: COMPARATOR
Intervention: Placebo, arbacet, misoprostol, sucralfate, and pirenzepine
Number of subjects: 86
Study 3081399 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal antiinflammatory drugs
Number of subjects: 86
Study 29705448 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural sounds for 30 minutes
Number of subjects: 180
Study 29705448 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical Turkish Music for 30 minutes
Number of subjects: 180
Study 29705448 — intervention group
Group type: EXPERIMENTAL
Intervention: Western Music for 30 minutes
Number of subjects: 180
Study 29705448 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 180
Study 27729323 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum free light chain (sFLC) measurements
Number of subjects: 113
Study 27729323 — intervention group
Group type: COMPARATOR
Intervention: Urine protein electrophoresis (UPEP)
Number of subjects: 113
Study 24646858 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean baseline 24‐h urinary sodium excretion of 3.46 g/day
Number of subjects: 840
Study 24646858 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine sodium under 3 g/day
Number of subjects: 840
Study 24646858 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine sodium ⩾ 3 g/day
Number of subjects: 840
Study 22531306 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal welding tonsillectomy
Number of subjects: 91
Study 22531306 — intervention group
Group type: COMPARATOR
Intervention: Cold knife tonsillectomy
Number of subjects: 91
Study 20447935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention colleges (15) with Campus Advisory Boards and facilitated activities
Number of subjects: 30
Study 20447935 — intervention group
Group type: COMPARATOR
Intervention: Control colleges (15)
Number of subjects: 30
Study 20447935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention colleges (15)
Number of subjects: 30
Study 18988091 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF50 sunscreen lotion
Number of subjects: 0
Study 18988091 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF50 sunscreen spray lotion
Number of subjects: 0
Study 16195164 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of the herbal remedy made from Rosa canina daily for 3 months
Number of subjects: 94
Study 16195164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 12866240 — intervention group
Group type: EXPERIMENTAL
Intervention: Training module for ultrasound-guided breast biopsy skills
Number of subjects: 12
Study 12866240 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 12
Study 12866240 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for USGBB in inexperienced residents (n = 4)
Number of subjects: 12
Study 12866240 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for USGBB in US-experienced residents (n = 2)
Number of subjects: 12
Study 12866240 — intervention group
Group type: COMPARATOR
Intervention: Untrained US-experienced residents (n = 3)
Number of subjects: 12
Study 10934079 — intervention group
Group type: EXPERIMENTAL
Intervention: Preovulatory phase (Days 5 to 11)
Number of subjects: 288
Study 10934079 — intervention group
Group type: EXPERIMENTAL
Intervention: Periovulatory phase (Days 12 to 18)
Number of subjects: 288
Study 10934079 — intervention group
Group type: EXPERIMENTAL
Intervention: Postovulatory phase (Days 19 to 25)
Number of subjects: 288
Study 10934079 — intervention group
Group type: EXPERIMENTAL
Intervention: Perimenstrual phase (Days 26 to 4)
Number of subjects: 288
Study 10934079 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall classification of ED visits by menstrual phase
Number of subjects: 288
Study 10934079 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma severity
Number of subjects: 288
Study 9505981 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 3350/electrolyte solution
Number of subjects: 57
Study 9505981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 57
Study 9505981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 9505981 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 57
Study 8445442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethamsylate (12.5 mg/kg) given prophylactically within the first 4 hours of life followed by 6-hourly doses for 4 days
Number of subjects: 20
Study 8445442 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 20
Study 3705790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 0
Study 3705790 — intervention group
Group type: COMPARATOR
Intervention: Support pessary
Number of subjects: 0
Study 31409166 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (400 mg cyclogest vaginal suppositories once daily)
Number of subjects: 100
Study 31409166 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone (250 mg of 17-hydroxyprogesterone caproate weekly)
Number of subjects: 100
Study 31558379 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus nutrition supplementation
Number of subjects: 180
Study 31558379 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 180
Study 31204416 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosomal Curcumin
Number of subjects: 65
Study 31204416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 29046364 — intervention group
Group type: EXPERIMENTAL
Intervention: IV prochlorperazine + diphenhydramine
Number of subjects: 127
Study 29046364 — intervention group
Group type: COMPARATOR
Intervention: IV hydromorphone
Number of subjects: 127